Burney Co. Sells 1,094 Shares of Jazz Pharmaceuticals PLC $JAZZ

Burney Co. cut its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,418 shares of the specialty pharmaceutical company’s stock after selling 1,094 shares during the quarter. Burney Co.’s holdings in Jazz Pharmaceuticals were worth $2,591,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in JAZZ. Hurley Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Picton Mahoney Asset Management raised its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 269 shares during the period. SVB Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $36,000. Hantz Financial Services Inc. raised its stake in shares of Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $138.38 on Tuesday. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The business has a 50-day simple moving average of $132.47 and a 200 day simple moving average of $118.61. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The stock has a market cap of $8.39 billion, a price-to-earnings ratio of -20.56, a PEG ratio of 8.49 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the previous year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of analyst reports. Wells Fargo & Company set a $170.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Morgan Stanley set a $183.00 price objective on Jazz Pharmaceuticals in a research note on Friday, October 24th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.